Genetic alterations, such as mutations of epidermal growth factor receptor (EGFR), KRAS, MET, and rearrangements of ALK and ROS1, are the main contributors to LC tumorigenesis and progression (5), which dysregulate proliferation, apoptosis, migration, and invasion of cancer cells through various downstream signaling pathways. This evidence concerns the gene MET and cancer.